Greater China
China's Ince raises $700m across two funds
Ince Capital, a Chinese venture capital firm established by J.P. Gan, formerly a managing partner at Qiming Venture Partners, has raised USD 700m for its second fund and for an accompanying vehicle aimed at later-stage opportunities.
TA promotes Hong Kong-based Andrew Tay to principal
TA Associates has promoted Andrew Tay, a Hong Kong-based investment professional, from director to principal.
China's Linear Capital raises $500m
Linear Capital, a China-based, technology-focused investment firm, has raised USD 500m for its fifth US dollar-denominated fund and its second opportunity Fund. It brings the firm’s total assets under management to USD 2bn.
China AI gaming company Parametrix raises $100m
Chinese artificial intelligence (AI) gaming company Parametrix.ai has raised a USD 100m Series B round led by Sequoia Capital China. Existing investors 5Y Capital and Gaorong Capital re-upped.
AGIC exits healthcare business Ritedose to Novo Holdings
AGIC Capital, which specializes in cross-border deals along the China-Europe axis, has agreed to sell pharmaceutical manufacturing and packaging business Ritedose Corporation to Novo Holdings.
China CDMO Thousand Oaks raises $240m
Thousand Oaks Biopharmaceuticals, a China-based contract development and manufacturing organization (CDMO), has raised CNY 1.5bn (USD 240m) in funding led by Goldstone Investment - a private equity unit of CITIC Securities - and CDH Investments.
Eastern Bell raises $2b across US dollar, renminbi funds
Eastern Bell Capital has closed its second US dollar-denominated fund and its sixth renminbi-denominated fund with aggregate commitments of more than CNY 13bn (USD 2bn).
China biotech player GenFleet raises $75m
GenFleet Therapeutics, a Chinese biotech developer focused on oncology and immunology, has secured a USD 75m Series C round led by Huagai Capital.
China's SenseTime perseveres with IPO despite blacklisting
Chinese artificial intelligence (AI) technology developer SenseTime has relaunched its IPO on the same terms, albeit excluding US investors, after being placed on another blacklist by the US government.
Hong Kong seeks compromise on local SPAC provisions
Hong Kong has compromised on several points of contention in its special purpose acquisition company (SPAC) guidelines, notably removing a requirement that investors can only redeem their shares post-merger if they vote against the deal.
ADV backs Asia, North America flooring manufacturer
ADV Partners has acquired a significant minority interest in CFL Technologies, a flooring materials business with a presence in multiple locations in the US, China, and Vietnam.
2022 preview: Healthcare
Healthcare’s high-cost, rapidly digitizing profile will persist regardless of how COVID-19 plays out in the coming years. China appears set for consolidation, including in biotech
Hong Kong's Brinc raises $130m for blockchain programs
Hong Kong accelerator Brinc has raised $130 million for blockchain-related accelerator programs and a global expansion with support from Animoca Brands, a local segment leader backed by several VCs.
2022 preview: China sustainability
Green-tech investment, from electric vehicles to renewable energy, is already in the ascendency as China ponders a carbon-neutral future. Momentum is expected to grow in 2022
2022 preview: China fundraising
Investors held fire on commitments to China managers amid uncertainty over regulatory reforms. Industry participants hope the government will provide clarity, but the fear LPs won’t hurry back
2022 preview: Macro & buyout
Will the bullish investment environment persist through 2022? Most Asia-based private equity players expect to remain busy, although they acknowledge a lack of visibility around macro and geopolitical risk
2022 preview: SaaS
Software-as-a-service continues to benefit from a digitalization push across multiple markets. Investors are looking for differentiation in a market characterized by high valuations and intense competition
China supermarket chain T11 raises $100m
T11, a China-based, technology-enabled supermarket chain, has raised a $100 million Series B led by Alibaba Group. Other investors include Redview Capital and MSA Capital.
Q&A: Legend Capital's Richard Li
Richard Li, president of Legend Capital, on evolving US-China relations, the logic behind the recent wave of regulation, investing in line with government policy, and why LPs should get used to onshore exits
Deal focus: Longreach eyes long overdue EnTie exit
Mindful of how political maneuvering has undone previous sale processes of Taiwan’s EnTie Commercial Bank, The Longreach Group is on edge as regulators prepare to rule on a $1.2 billion tie-up with IBF Financial
2021 in review: Boom time
Cheap debt and a desire for assets that deliver technology-driven growth have propelled Asia private equity investment to new highs and supported a resurgence in exits. But fundraising still fails to convince
China's Avistone Pharmaceuticals raises $200m
Avistone Pharmaceuticals, a Beijing biotech company focused on precision oncology therapeutics has raised more than $200 million in a Series A funding round led by Vivo Capital.
Biotech player CANbridge drops on debut after $87m HK IPO
CANbridge Pharmaceuticals, a Beijing-based drug developer that focuses on treatments for cancer and rare diseases, lost 27% in value on its Hong Kong trading debut following a HK$685.1 million ($87.8 million) IPO.
Blue Owl buys Asia-based placement agent
US alternative asset manager Blue Owl Capital has acquired Hong Kong placement agent Ascentium with a view to establishing a physical presence in the territory and pursuing a broader regional expansion.